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Abstract. Background/Aim: Hepatocellular carcinoma is a
substantial healthcare burden with high prevalence and poor
prognosis. As such, efforts are continually made to uncover
molecules relevant in cancer biology, that are exploitable as
targets for therapy. The mitochondrion is the powerhouse of
the cell and exhibits altered functionality in the malignant
state, including aberrant regulation of apoptosis and cellular
respiration. Augmenter of liver regeneration (ALR) is a
multifunctional mitochondrial protein that demonstrates anti-
oxidative and anti-apoptotic properties and plays a key role
in liver regeneration. Materials and Methods: The present
study systematically reviews the available literature on the
role of ALR in cancer. Results: Systematic search of PubMed
resulted in 12 studies discussing ALR in multiple types of
cancer. More specifically, ALR appears to be up-regulated in
malignant cells and tissues. Furthermore, treatment of cells
with exogenous ALR shows an anti-apoptotic effect while
silencing or inhibiting ALR decreases cell and tumor
survival. Conclusion: ALR clearly plays a role in cancer
biology and demonstrates potential as a therapeutic target.
Hepatocellular carcinoma (HCC) is a common oncologic
condition with a poor prognosis that poses as a global burden
on medical care (1). Between 2002 and 2012 the mortality
rate of HCC rose by 34.8% in the United States and liver
cancer, with HCC estimated as 70 to 90% of cases, was
considered to be the second leading cause of cancer-related
deaths among males on a global scale in 2012 (2, 3).
Considering the metabolic aspect of several known risk
factors for HCC, such as obesity, diabetes, and non-alcoholic
fatty liver disease, a common underlying feature of
mitochondrial dysfunction is of growing interest in molecular
oncology. The regulation of specific mitochondrial proteins
is of particular interest, as these proteins demonstrate
potential as therapeutic targets for HCC (4).
Augmenter of liver regeneration (ALR) is one particular
protein of interest that localizes in the intermembrane space of
the mitochondria of humans and has a prokaryotic homolog,
Erv1, sharing 42% identical amino acid residues. ALR/Erv1
has been known to contribute to mitochondrial biogenesis and
function as a sulfhydryl oxidase in mitochondrial disulfide
relay systems (5). It functions to oxidize the import receptor
Mia40, both of which conjunctively import small translocase
inner membrane (Tim) proteins through an oxidative-folding
pathway (6). In turn, cytochrome c (cyt c), which constitutes
an important member of the electron transport chain, oxidizes
ALR through locomotion of electrons via FAD, thus
connecting this redox regulated import pathway to electron
transport (5, 7). During specific unfavorable conditions, cells
must reprogram to undergo apoptosis during which cyt c
activates a series of activated-caspase pathways that lead to cell
suicide (8). It is a trademark of cancer cells to down-regulate
apoptotic mechanisms and alter mitochondrial respiratory
function, resulting in uncontrolled growth and eventual
metastasis of cancerous cells. ALR manifests anti-oxidative and
anti-apoptotic properties and is known to support liver
regeneration in cases of hepatic injury (9). Considering these
properties, early investigations have suggested a role for ALR
in cancer (particularly hepatocellular) pathogenesis, growth and
progression. In this study, we systematically review the
literature discussing ALR in cancer. Clinical implications
including oncogenesis and targeted therapy are explored. 
Materials and Methods
A systematic review was performed using the National Library of
Medicine PubMed database. The search was performed using the
following key terms: cancer and augmenter of liver regeneration,
growth factor erv1-like, GFER, or hepatic regenerative stimulation
3379
This article is freely accessible online.
Correspondence to: Dr. Deepa V. Dabir, 1 LMU Drive, Department
of Biology, Loyola Marymount University, Los Angeles, CA 90045,
USA. Tel: +1 3103384200, e-mail: ddabir@lmu.edu
Key Words: Augmenter of liver regeneration, ALR, malignancy,
review.
ANTICANCER RESEARCH 37: 3379-3383 (2017)
doi:10.21873/anticanres.11704
Review
Clinical Implications of Augmenter of Liver Regeneration 
in Cancer: A Systematic Review
KEVIN H. NGUYEN, AUSTIN H. NGUYEN and DEEPA V. DABIR 
Department of Biology, Loyola Marymount University, Los Angeles, CA, U.S.A.
substance. Articles were screened by titles and abstracts for possible
relevance. Subsequently, full-text articles were retrieved for final
inclusion decision. Inclusion criteria were: discussion of ALR in
cancer, written in English, use of human subjects/samples. Conference
abstracts and literature reviews were excluded from the present study.  
Results
Systematic search of PubMed initially returned 41 articles,
shown in Figure 1. Screening by titles and abstracts
eliminated 28 articles. Full-text review eliminated one article
that was an editorial and did not contain original data.
Ultimately, 12 articles were included in the present review
(10-21). Study characteristics are summarized in Table I.
Hepatocellular carcinoma. Results of studies investigating
ALR in cancer are summarized in Table II. The majority of
included studies observe ALR to be upregulated in malignant
cells. In frozen and paraffin-embedded HCC tissue, ALR
expression is consistently altered when compared to normal
para-tumoral tissue and/or healthy controls (10, 11, 13, 20,
21). The majority of studies suggest ALR mRNA and protein
levels to be higher in HCC tissue relative to normal tissue.
In HCC tissue, ALR typically demonstrates cytoplasmic
localization with a granular quality on immunostaining (20).
Dayoub and colleagues, however, observe the short ALR
isoform of 15 kDa to be expressed at lower levels in HCC
overall, compared to normal liver tissue (11). Furthermore,
this study found ALR expression to be inversely correlated
with tumor grade and histologic angioinvasion. No other
studies specified the isoform of ALR investigated.
Additionally, one study demonstrated serum ALR levels to
be unchanged in patients with HCC (21).
The bulk of studies investigated the role of ALR in cancer
biology using HCC cell lines. In vitro, ALR is consistently
associated with a protective effect on cancer cell survival and
ANTICANCER RESEARCH 37: 3379-3383 (2017)
3380
Table I. Summary of study details investigating ALR in cancer.
Study                                     Cancer              N                N       Gender  Mean age                 Tissue                                           Assays
                                                type             (total)        (cancer)     M:F       (range)
Cao et al., 2009                     HCC               11               11           9:2    54.1 (37-66)               Frozen                                qPCR, H2DCF-DA, 
                                                                                                                                                                                                    flow cytometry
Dayoub et al., 2011               HCC               64               53            -                -           Cell line HepG2, FFPE        IHC, migration/invasion assays, 
                                                                                                                                                                                                      RT-PCR, WB
Denk et al., 2010                   HCC                 -                  -              -                -                 Cell line HuH-7               WB, PCR, formazan formation 
                                                                                                                                                                                                 cell viability assay
Gandhi et al., 2015                HCC                 -                  -              -                -                     FFPE, mice                 IHC, WB, RT-PCR, transmission 
                                                                                                                                                                                                electron microscopy
Gatzidou et al., 2015             CRC               42               23        11:12         68.8        Cell lines, frozen tissue                              qPCR
Ilowski et al., 2011              Various               -                  -              -                -                      Cell lines                                     WB, FACS
Polimeno et al., 2009    Neuroblastoma        -                  -              -                -              Cell line SH-SY5Y     Cell viability, flow cytometry, ICC, WB
Polimeno et al., 2012          Glioma               -                  -              -                -                  Cell line T98G                    WB, ICC, flow cytometry, 
                                                                                                                                                                                                electron microscopy
Shen et al., 2013           T cell leukemia        -                  -              -                -                  Cell line Jurkat             Cell viability, flow cytometry, WB
Tang et al., 2009                    HCC                 -                  -              -                -            Cell line HepG2, mice       ICC, RT-PCR, mouse tumor model
Thasler et al., 2005                HCC               71                9           5:4           66.2        FFPE, cell line HepG2                   IHC, RT-PCR, WB
Yu et al., 2010                       HCC         Serum: 72  Serum: 20      -                -                   Serum, FFPE                         ELISA, RT-PCR, IHC
                                                                 Tissue: 58   Tissue: 6
ALR: Augmenter of liver regeneration; CRC: colorectal cancer; FACS: fluorescence-activated cell sorting; FFPE: formalin-fixed paraffin embedded;
HCC: hepatocellular carcinoma; ICC: immunocytochemistry; IHC: immunohistochemistry; PCR: polymerase chain reaction; RT-PCR: reverse-
transcription polymerase chain reaction; WB: western blot.
Figure 1. Systematic review of PubMed for articles discussing the
clinical value of ALR in cancer. Initial search returned 41 articles.
Screening by titles, abstracts, and full texts resulted in 12 articles
remaining for final inclusion in this review. 
apoptosis. Cao et al. observed overexpression of ALR in
HCC cells to have a protective effect against radiation-
induced mitochondrial dysfunction and subsequent apoptosis
(10). Additionally, treatment of HCC cells with ALR has a
protective effect against apoptosis induced by ethanol,
TRAIL, anti-Apo, TGF-β, and actinomycin D (15). 
Silencing of ALR consistently demonstrated an anti-
tumoral effect in HCC. Upon ALR silencing, overall growth
and survival of HCC cells was inhibited, while a minimal
effect was noted in normal hepatocyte cells (10, 19). In a
murine HCC xenograft model, silencing of ALR and
treatment with anti-ALR monoclonal antibodies both
similarly inhibited tumor growth (19). Only one study
reported that lowered ALR expression has been linked to
HCC oncogenesis. In this study, mice with a liver-specific
ALR knock-out were observed to have increased
hepatosteatosis, hepatocyte apoptosis, and elevated HCC
incidence of 60% at one year (13).
Nguyen et al: ALR in Cancer (Review)
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Table II. Summary of clinical implications of ALR in cancer.
Study                                Cancer         Findings
Cao et al., 2009                 HCC           • ALR is up-regulated by greater than twofold in 81.9% of HCC specimens, 
                                                                 compared to adjacent noncancerous tissue
                                                              • Overexpression of ALR in HCC cell lines was associated with increased survival after irradiation, 
                                                                 attenuates post-irradiation mitochondrial dysfunction, and inhibits mitochondria-dependent apoptosis
                                                              • ALR silencing inhibited growth and survival of HCC lines, but had minimal effect 
                                                                 on normal hepatocyte cells
Dayoub et al.,                   HCC           • The short ALR isoform of 15 kDa is expressed less in HCC cells, compared to normal liver tissue
2011                                                       • Reexpression of the 15 kDa ALR isoform in HCC cells reduces migration and invasiveness and 
                                                                 attenuates tumorigenicity
                                                              • ALR expression in HCC tissue inversely correlates with tumor grade and rate of histological angioinvasion
Denk et al., 2010              HCC           • Transfection of HCC cells with ALR does not decrease apoptosis after treatment with 
                                                                 glycochenodeoxycholic acid 
Gandhi et al.,                    HCC           • Liver-specific ALR knock-out mice demonstrated decreased mitochondrial respiratory function, 
2015                                                         defective mitochondrial fatty acid transport and ATP synthesis
                                                              • They also demonstrated increased oxidative stress, steatosis, hepatocyte apoptosis, mitochondrial 
                                                                 structural abnormalities
                                                              • HCC developed in nearly 60% of liver-specific ALR knock-out mice by 1 year
                                                              • ALR levels were lower in patients with advanced alcoholic liver disease and nonalcoholic 
                                                                 steatohepatitis compared to controls
Gatzidou et al.,                 CRC           • ALR was expressed at higher levels in CRC cell lines compared to controls
2015                                                       • ALR expression was significantly increased in well/moderately differentiated tumors compared to 
                                                                 poorly differentiated tumors
                                                              • ALR tended to be higher in CRC tissue compared to matched non-neoplastic tissue
Ilowski et al.,                 Various         • HCC cells cultured in rhALR significantly decreased apoptosis induced by ethanol, TRAIL, anti-Apo, 
2011                                                         TGF-β, and actinomycin D
                                                              • rhALR treatment did not reduce apoptosis in bronchial, colonic, gastric, and pancreatic cell lines
Polimeno et al.,        Neuroblastoma   • Neuroblastoma cells cultured with ALR exhibited improved survival in H2O2-induced apoptosis
2009
Polimeno et al.,              Glioma         • Glioma cells treated with rhALR dose-dependently decreased ROS levels in H2O2-treated cells
2012                                                       • Silencing of ALR-endcoding mRNA decreased clusterin and bcl-2 levels and increased 
                                                                 apoptosis and apoptotic markers caspase-9, activated caspase-3, ROS, and mitochondrial degeneration
Shen et al., 2013              T cell          • Leukemic T cells show upregulation of ALR compared to normal T lymphocyte controls
                                       leukemia        • Culture of leukemic T cells with ALR reduces sensitivity to vincristine treatment 
                                                                 but does not effect proliferation
Tang et al., 2009               HCC           • Silencing of ALR inhibited growth of HCC cells in vitro
                                                              • Silencing of ALR and treatment of anti-ALR monoclonal antibodies both inhibited 
                                                                 xenografted HCC tumors in nude mice
Thasler et al., 2005           HCC           • HCC tissue demonstrated intense cytoplasmic granular immunostaining for ALR
                                                              • ALR mRNA expression in HCC tissue was significantly higher compared with normal liver tissue samples
Yu et al., 2010                   HCC           • Serum ALR levels did not differ among patients with HCC, chronic hepatitis B, and healthy controls
                                                              • ALR mRNA and protein levels were significantly higher in HCC liver tissues compared to healthy controls
ALR: Augmenter of liver regeneration; CRC: colorectal cancer; HCC: hepatocellular carcinoma; rhALR: recombinant human ALR; ROS: reactive
oxygen species; TGF-β: transforming growth factor beta; TRAIL: tumor necrosis factor related apoptosis-inducing ligand.
Other cancers. Five studies discussed cancers other than HCC
(14, 15, 16, 17, 18). Gatzidou and colleagues observed
elevated ALR levels in colorectal cancer (CRC) tissue and cell
lines when compared to matched non-neoplastic tissue or
controls, respectively (14). Similar to HCC, ALR expression
in malignant tissue was inversely correlated with tumor grade.
Namely, ALR was elevated in well to moderately
differentiated tumors when compared to poorly differentiated
ones. In another study, in vitro treatment with ALR does not
appear to reduce apoptosis in bronchial, colonic, gastric, and
pancreatic malignant cell lines (15). In T cell leukemia,
cultured cells were observed to upregulate ALR compared to
normal primary T lymphocytes (18). Furthermore, treatment
with ALR reduces leukemic T cell sensitivity to vincristine.
ALR is of interest in neuronal tissue as well. Both
neuroblastoma and glioma cells cultured with ALR exhibit a
dose-dependent improvement in survival in H2O2-induced
apoptosis (16, 17). Furthermore, silencing of ALR in glioma
cells induces a pro-apoptotic state with increased reactive
oxygen species generation and mitochondrial degeneration.
Discussion
Expression of ALR as assessed by varied qualitative and
quantitative assays is clearly altered in malignancy. In light
of the multifunctional nature of mitochondria, ALR likely
plays a central role in cancer biology, in apoptotic regulation
and cell respiration. In HCC tissues, ALR was consistently
increased compared to healthy controls with the exception of
one study which specifically investigated the 15 kDa
isoform. Via alternative splicing, ALR may be found as a
21/23-kDa isoform predominantly in the mitochondrial inter
membrane space or as a 15-kDa isoform at extracellular,
nuclear, and cytoplasmic localizations (11). This likely
accounts for the inconsistencies in ALR levels found across
the included studies. In HCC, the malignant state may be
associated with an altered expression profile of ALR that is
preferential for the larger isoform. This would also explain
the oncogenic effect of ALR knock-out in mice (13). If the
15-kDa isoform is associated with healthy hepatocytes while
the longer isoform is upregulated in malignancy, a pan-ALR
knock-out may be oncogenic. Further investigation
dissecting the specific functions of the ALR isoforms in
healthy cell and cancer biology is necessary. 
ALR demonstrates potential as a therapeutic target in
cancer treatment. Sufficient in vitro evidence suggests ALR
silencing to be anti-tumoral. Silencing and/or inhibiting ALR
in an HCC xenograft nude mouse model showed promising
anti-tumor effect (19). However, considering oncogenic effect
and increased hepatosteatosis in the murine liver-specific
knock-out of ALR (13), further elucidation of the roles of the
ALR isoforms must be performed. Perhaps specific targeting
of the 21/23-kDa isoform may minimize adverse outcome.
Overall, the currently available literature clearly suggests an
oncogenic role of ALR in cancer biology. However, the complete
function of ALR in cancer is not fully understood. Further
investigations need to be performed on ALR function in tumor
progression and as a targeted therapy. This early evidence,
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